United States securities and exchange commission logo





                              November 30, 2022

       Chee Kong Choo
       Director and Chairman
       CytoMed Therapeutics Pte. Ltd.
       21 Bukit Batok Crescent
       #17-80 WCEGA Tower
       Singapore 658065

                                                        Re: CytoMed
Therapeutics Pte. Ltd.
                                                            Registration
Statement on Form F-1
                                                            Filed November 18,
2022
                                                            File No. 333-268456

       Dear Chee Kong Choo:

              We have reviewed your registration statement and have the
following comments. In
       some of our comments, we may ask you to provide us with information so
we may better
       understand your disclosure.

              Please respond to this letter by amending your registration
statement and providing the
       requested information. If you do not believe our comments apply to your
facts and
       circumstances or do not believe an amendment is appropriate, please tell
us why in your
       response.

              After reviewing any amendment to your registration statement and
the information you
       provide in response to these comments, we may have additional comments.

       Registration Statement on Form F-1

       Cover Page

   1.                                                   Revise the disclosure
on the cover page to clarify whether the offering is contingent upon
                                                        final approval of your
NASDAQ listing. Please ensure the disclosure is consistent with
                                                        your underwriting
agreement.
       Risks Related to Investments in Singapore Companies, page 68

   2.                                                   In the new risk factor
on page 70 you disclose that Singapore taxes may differ from the
                                                        tax laws of other
jurisdictions and advise potential investors to consult with their own tax
                                                        advisors; however, you
provide no context regarding the nature of the potential risks.
                                                        Please revise explain
the risks you are attempting to convey.
 Chee Kong Choo
CytoMed Therapeutics Pte. Ltd.
November 30, 2022
Page 2
Business
Patent License, page 115

3.    Revise to disclose the term of the third extension of the patent license.
Exhibits

4.    Prior to effectiveness, file actual consents of all persons who will
become directors, rather
      than "Form of" consents, or revise the exhibit index to clarify you have
done so.
        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence of
action by the staff.

       Refer to Rules 460 and 461 regarding requests for acceleration. Please
allow adequate
time for us to review any amendment prior to the requested effective date of
the registration
statement.

        You may contact Tracie Mariner at (202) 551-3744 or Daniel Gordon at
(202) 551-3486
if you have questions regarding the financial statements and related matters.
Please contact
Abby Adams at (202) 551-6902 or Celeste Murphy at (202) 551-3257 with any other
questions.



                                                             Sincerely,
FirstName LastNameChee Kong Choo
                                                             Division of
Corporation Finance
Comapany NameCytoMed Therapeutics Pte. Ltd.
                                                             Office of Life
Sciences
November 30, 2022 Page 2
cc:       Richard I. Anslow, Esq.
FirstName LastName